Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-109380 · Präparat HOS-093187
Tabulated list of adverse reactions
The following adverse reactions were reported for patients who received parecoxib (N=5,402) in
28 placebo-controlled clinical trials. Reports from post-marketing experience have been listed as
“frequency not known” because the respective frequencies cannot be estimated from the available
data. Within each frequency grouping, adverse reactions are listed using MedDRA terminology and
presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage ea4e92895cd67d8c373fa7758cef8d88c6e6aeb698681d30923aa118a4a4cbd6 · Zeichen 676–1142 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-109381 · Präparat HOS-093187
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Infections and infestations
Pharyngitis, Abnormal sternal
alveolar osteitis serous wound
(dry socket) drainage, wound
infection
Blood and lymphatic system disorders
Anaemia Thrombocytopenia
postoperative
Immune system disorders
Anaphylactoid
reaction
Metabolism and nutrition disorders
Hypokalaemia Hyperglycaemia,
anorexia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 383dccd2bd05f953fc264bae55e1cba066d567c70d2b90b39e1af3f0a74c0ceb · Zeichen 1145–1992 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 9–10
HOS-109382 · Präparat HOS-093187
9
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Psychiatric disorders
Agitation,
insomnia
Nervous system disorders
Hypoaesthesia, Cerebrovascular
dizziness disorder
Ear and labyrinth disorders
Ear pain
Cardiac disorders
Myocardial Circulatory
infarction, collapse,
bradycardia congestive heart
failure, tachycardia
Vascular disorders
Hypertension, Hypertension
hypotension (aggravated),
orthostatic hypotension
Respiratory, thoracic and mediastinal disorders
Respiratory Pulmonary Dyspnoea
insufficiency embolism
Gastrointestinal disorders
Nausea Abdominal pain, Gastroduodenal Pancreatitis,
vomiting, ulceration, oesophagitis,
constipation, gastrooesophageal oedema mouth
dyspepsia, reflux disease, dry (perioral
flatulence mouth, gastrointestinal swelling)
sounds abnormal
Skin and subcutaneous tissue disorders
Pruritus, Ecchymosis, rash, Stevens-Johnson
hyperhidrosis urticaria syndrome,
erythema
multiforme,
exfoliative
dermatitis
Musculoskeletal and connective tissue disorders
Back pain Arthralgia
Renal and urinary disorders
Oliguria Renal failure Renal failure,
acute
General disorders and administration site conditions
Oedema Asthenia, injection site Hypersensitivity
peripheral pain, injection site reactions
reaction including
anaphylaxis and
angioedema
Investigations
Blood Blood CPK
creatinine increased, blood
increased LDH increased,
SGOT increased,
SGPT increased,
BUN increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 77bf310e6d4a5958412f6e7d674e27848a9a36ad27ce762d6bbcda6922a31f8f · Zeichen 2046–5232 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 10–11
HOS-109383 · Präparat HOS-093187
10
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Injury, poisoning and procedural complications
Post procedural
complication (skin)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage ab588fedb0f7b049e9453376be0854f1371fc2287e4bc1591e068a6f9ecdf5b8 · Zeichen 5280–5677 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 11
HOS-109384 · Präparat HOS-093187
Description of selected adverse reactions
In post-marketing experience, toxic epidermal necrolysis has been reported in association with the use
of valdecoxib, and cannot be ruled out for parecoxib (see section 4.4). In addition, the following rare,
serious adverse reactions have been reported in association with the use of NSAIDs and cannot be
ruled out for Dynastat: bronchospasm and hepatitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage c2f84753a3b9a19e5de5032128c43975a8262835c36f2db555d7477c7ea4a0c9 · Zeichen 5679–6077 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 11
HOS-109385 · Präparat HOS-093187
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 6079–6434 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-109416 · Präparat HOS-093187
Summary of the safety profile
The most common adverse reaction for Dynastat is nausea. The most serious reactions occur
uncommonly to rarely, and include cardiovascular events such as myocardial infarction and severe
hypotension, as well as hypersensitivity events such as anaphylaxis, angioedema and severe skin
reactions. Following coronary artery bypass graft surgery, patients administered Dynastat have a
higher risk of adverse reactions such as: cardiovascular/thromboembolic events (including myocardial
infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep
surgical infections, and sternal wound healing complications.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage f11dc4f8e4d213fbd685966e6163e7d9f0e2c35f5cefa4508a568648a43ac8b5 · Zeichen 0–673 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-109417 · Präparat HOS-093187
Tabulated list of adverse reactions
The following adverse reactions were reported for patients who received parecoxib (N=5,402) in
28 placebo-controlled clinical trials. Reports from post-marketing experience have been listed as
“frequency not known” because the respective frequencies cannot be estimated from the available
data. Within each frequency grouping, adverse reactions are listed using MedDRA terminology and
presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage ea4e92895cd67d8c373fa7758cef8d88c6e6aeb698681d30923aa118a4a4cbd6 · Zeichen 675–1141 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 25–26
HOS-109418 · Präparat HOS-093187
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Infections and infestations
Pharyngitis, Abnormal sternal
alveolar osteitis serous wound
(dry socket) drainage, wound
infection
Blood and lymphatic system disorders
Anaemia Thrombocytopenia
postoperative
Immune system disorders
Anaphylactoid
reaction
Metabolism and nutrition disorders
Hypokalaemia Hyperglycaemia,
anorexia
25
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Psychiatric disorders
Agitation,
insomnia
Nervous system disorders
Hypoaesthesia, Cerebrovascular
dizziness disorder
Ear and labyrinth disorders
Ear pain
Cardiac disorders
Myocardial Circulatory
infarction, collapse,
bradycardia congestive heart
failure, tachycardia
Vascular disorders
Hypertension, Hypertension
hypotension (aggravated),
orthostatic hypotension
Respiratory, thoracic and mediastinal disorders
Respiratory Pulmonary Dyspnoea
insufficiency embolism
Gastrointestinal disorders
Nausea Abdominal pain, Gastroduodenal Pancreatitis,
vomiting, ulceration, oesophagitis,
constipation, gastrooesophageal oedema mouth
dyspepsia, reflux disease, dry (perioral
flatulence mouth, gastrointestinal swelling)
sounds abnormal
Skin and subcutaneous tissue disorders
Pruritus, Ecchymosis, rash, Stevens-Johnson
hyperhidrosis urticaria syndrome,
erythema
multiforme,
exfoliative
dermatitis
Musculoskeletal and connective tissue disorders
Back pain Arthralgia
Renal and urinary disorders
Oliguria Renal failure Renal failure,
acute
General disorders and administration site conditions
Oedema Asthenia, injection site Hypersensitivity
peripheral pain, injection site reactions
reaction including
anaphylaxis and
angioedema
Investigations
Blood Blood CPK
creatinine increased, blood
increased LDH increased,
SGOT increased,
SGPT increased,
BUN increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 9fe08117c192f80e2a3a35ad5decacee319863fb938db0d12245997859215a75 · Zeichen 1144–5182 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 26–27
HOS-109419 · Präparat HOS-093187
26
Adverse Drug Reaction Frequency
Very Common Common Uncommon Rare (1/10,000 Not known
(1/10) (1/100 to (1/1000 to <1/100) to <1/1000)
<1/10)
Injury, poisoning and procedural complications
Post procedural
complication (skin)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage ae5a0ac9713922c845515397bb4f9359d4ea27add047a6c5ffe396a9796cd1f3 · Zeichen 5230–5620 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 27
HOS-109420 · Präparat HOS-093187
Description of selected adverse reactions
In post-marketing experience, toxic epidermal necrolysis has been reported in association with the use
of valdecoxib, and cannot be ruled out for parecoxib (see section 4.4). In addition, the following rare,
serious adverse reactions have been reported in association with the use of NSAIDs and cannot be
ruled out for Dynastat: bronchospasm and hepatitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage c2f84753a3b9a19e5de5032128c43975a8262835c36f2db555d7477c7ea4a0c9 · Zeichen 5622–6020 im Abschnitt
Nebenwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 27
HOS-109421 · Präparat HOS-093187
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 6022–6377 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.